nerve growth factor
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03470038 | Mar → May 2018 | — | Aalborg University | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01163825 | Jan 2008 → Dec 2011 | Alzheimer disease | NsGene A/S | Unknown | No outcome recorded |
| Phase 1 | NCT00017940 | ? → Nov 2003 | Alzheimer disease | The Shiley Family Trust | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03968042 | Jun 2019 → Dec 2021 | brain injury | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | Mixed |
| Phase 2 | NCT01212679 | Dec 2010 → Oct 2017 | traumatic brain injury | Jinling Hospital, China | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06391645 | May 2024 → Dec 2025 overdue | amyotrophic lateral sclerosis | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05231694 | Apr 2022 → Sep 2025 | ischemic stroke | The Third Affiliated hospital of Zhejiang Chinese Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03686163 | Jan 2016 → Dec 2019 | ischemic stroke | Jinling Hospital, China | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT05652751 Comparator | Mar 2022 → Feb 2023 | ischemic stroke | The Third Affiliated hospital of Zhejiang Chinese Medical University | Unknown | No outcome recorded |
| — | NCT03354624 Background | Nov 2017 → Feb 2018 | — | Aalborg University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-08-22 | Dompé Farmaceutici S.p.A | Regulatory Dompé receives FDA approval cenegermin eye drops, first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis dompe.com ↗
Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved cenegermin, a breakthrough therapy for neurotrophic keratitis (NK), a rare and progressive eye disease that can lead to corneal scarring and vision loss. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-22 | Dompé Farmaceutici S.p.A | Dompé receives FDA approval cenegermin eye drops, first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis dompe.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nerve Growth Factor | “Intramuscular injection of Nerve Growth Factor (NGF) may influence the responsiveness of active chemo-sensitive channels affecting muscle pain sensitivity.” PMID 31314952 ↗ Aug 20198“The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China.” NCT05231694 ↗ |
| Known as | Human Nerve Growth Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00017940 ↗ |
| Known as | Jinlujie | “The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from...” NCT05652751 ↗1“The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China.” NCT05231694 ↗ |
| Known as | Nerve Growth Factors | “Drug: Nerve Growth Factors” NCT03686163 ↗ |
| Known as | NGF | “The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from...” NCT05652751 ↗6“AIMS: To measure the therapeutic effect of an anti-oxidant, edaravone (EDV), or neurotrophic treatment with nerve growth factor (NGF) as an add-on treatment for alcohol-related...” PMID 38049955 ↗ Dec 2023 “Nerve growth factor (NGF) stimulates cholinergic function, improves memory and prevents cholinergic degeneration in animal models of injury, amyloid overexpression and aging.” PMID 15852017 ↗ Apr 2005 “Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells” NCT01163825 ↗ “Sterile solutions of recombinant human nerve growth factor (NGF)” NCT03354624 ↗ “Nerver growth factor (NGF) injection” NCT05231694 ↗ |
| Known as | NO.S20060051 | “The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from...” NCT05652751 ↗1“The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China.” NCT05231694 ↗ |
| Known as | rhNGF | “The phase I clinical trial of intravenous recombinant human nerve growth factor (rhNGF) showed that, on the premise of ensuring safety, only a trace of NGF (3.6-7.38 ng/ml...” NCT06391645 ↗ |
| Modality | Cell therapy | “implanting autologous fibroblasts genetically modified to express human NGF into the forebrain” PMID 15852017 ↗ Apr 2005 |
| Route | Other | “patients will receive intracerebral injections of their own primary fibroblasts” NCT00017940 ↗ |